» Articles » PMID: 38337535

Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Feb 10
PMID 38337535
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertrophic cardiomyopathy (HCM) is characterized by abnormal growth of the myocardium with myofilament disarray and myocardial hyper-contractility, leading to left ventricular hypertrophy and fibrosis. Where culprit genes are identified, they typically relate to cardiomyocyte sarcomere structure and function. Multi-modality imaging plays a crucial role in the diagnosis, monitoring, and risk stratification of HCM, as well as in screening those at risk. Following the recent publication of the first European Society of Cardiology (ESC) cardiomyopathy guidelines, we build on previous reviews and explore the roles of electrocardiography, echocardiography, cardiac magnetic resonance (CMR), cardiac computed tomography (CT), and nuclear imaging. We examine each modality's strengths along with their limitations in turn, and discuss how they can be used in isolation, or in combination, to facilitate a personalized approach to patient care, as well as providing key information and robust safety and efficacy evidence within new areas of research.

Citing Articles

Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology.

Mlynarska E, Radzioch E, Dabek B, Leszto K, Witkowska A, Czarnik W Biomedicines. 2025; 12(12.

PMID: 39767581 PMC: 11727519. DOI: 10.3390/biomedicines12122675.

References
1.
Ommen S, Mital S, Burke M, Day S, Deswal A, Elliott P . 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142(25):e558-e631. DOI: 10.1161/CIR.0000000000000937. View

2.
OMahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C . A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2013; 35(30):2010-20. DOI: 10.1093/eurheartj/eht439. View

3.
Joy G, Kelly C, Webber M, Pierce I, Teh I, McGrath L . Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and Overt Hypertrophic Cardiomyopathy. Circulation. 2023; 148(10):808-818. PMC: 10473031. DOI: 10.1161/CIRCULATIONAHA.123.063835. View

4.
Greenberg M, Tardiff J . Complexity in genetic cardiomyopathies and new approaches for mechanism-based precision medicine. J Gen Physiol. 2021; 153(3). PMC: 7852459. DOI: 10.1085/jgp.202012662. View

5.
Cannon 3rd R, Dilsizian V, OGara P, Udelson J, Tucker E, Panza J . Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation. 1992; 85(3):1039-45. DOI: 10.1161/01.cir.85.3.1039. View